A Phase 1, Open-label, Randomized, 2-period, Crossover Study to Assess the Effect of Intravenous Infusion of Piperacillin/Tazobactam on the Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) in Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 13 Jun 2018
Price : $35 *
At a glance
- Drugs Lumicitabine (Primary) ; Piperacillin/tazobactam
- Indications Metapneumovirus infections; Parainfluenza virus infections; Respiratory syncytial virus infections
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 06 Jun 2018 Status changed from active, no longer recruiting to completed.
- 24 Apr 2018 Status changed from recruiting to active, no longer recruiting.
- 27 Feb 2018 New trial record